शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

AMRUTANJANNSEAMRUTAJAN HEALTH LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 3 Nov, 2026 · 18:12 IST

Standalone Q2 FY27 revenue up 14.9%, profit after tax up 23.8%

EBITDA margin expansionNegative operating cash flowResults View source PDFExplain this filing

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.9%Reaction day
₹498.00
prior close
₹525.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+2.2%+0.7% vs market
Pharmaceuticals peers, median of 173sector+0.8%+2.1% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.6
10m
-2.0
15m
-1.6
30m
-1.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.9+2.2+0.7+0.8+2.1
Next day
+4.3+3.3+1.0+1.6+2.7
2d
+3.1pendingpending+1.5+1.7
3d
—————
4d
—————
5d
—————
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unaudited standalone results for the quarter ended 30 September 2026: revenue was Rs 135.18 crore, up 14.9% year on year from Rs 117.70 crore, and profit after tax was Rs 17.28 crore, up 23.8% from Rs 13.96 crore. Operating earnings before interest, tax, depreciation and amortisation improved from 14.0% to 17.5% of revenue. Standalone half-year operating cash flow was negative Rs 2.16 crore. A first interim dividend of Rs 1 per share was declared.

Likely market impact

Positive earnings and the Rs 1 dividend support sentiment, but negative half-year operating cash flow and capital spending are concerns.

By the numbersStandalone · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹135.2 Cr₹117.7 Cr+14.9%
Operating profit₹20.08 Cr₹14.92 Cr+34.6%
Profit after tax₹17.28 Cr₹13.96 Cr+23.8%
EBITDA margin17.5%14.0%+3.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.